Media coverage about Aldeyra Therapeutics (NASDAQ:ALDX) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aldeyra Therapeutics earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 48.1628946571111 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of Aldeyra Therapeutics (ALDX) opened at $6.80 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 20.35 and a current ratio of 20.35. Aldeyra Therapeutics has a 1-year low of $3.80 and a 1-year high of $11.90.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. equities analysts forecast that Aldeyra Therapeutics will post -1.39 EPS for the current year.

A number of equities analysts have recently weighed in on the company. Zacks Investment Research upgraded Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research note on Thursday, August 10th. HC Wainwright set a $18.00 target price on Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. ValuEngine upgraded Aldeyra Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 12th. Canaccord Genuity restated a “buy” rating and issued a $27.00 target price (up previously from $12.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, September 13th. Finally, Cantor Fitzgerald assumed coverage on Aldeyra Therapeutics in a research note on Tuesday, October 24th. They issued an “overweight” rating and a $22.00 target price on the stock. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $17.29.

In related news, major shareholder Life Sciences Maste Perceptive purchased 200,000 shares of the stock in a transaction that occurred on Tuesday, September 19th. The shares were bought at an average price of $7.25 per share, with a total value of $1,450,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 19.04% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-aldeyra-therapeutics-aldx-stock-price/1734359.html.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Insider Buying and Selling by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.